nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—systemic lupus erythematosus	0.289	1	CbGaD
Valsartan—SLCO1B3—Mycophenolate mofetil—systemic lupus erythematosus	0.129	0.247	CbGbCtD
Valsartan—SLCO1B1—Mycophenolate mofetil—systemic lupus erythematosus	0.0749	0.144	CbGbCtD
Valsartan—SLCO1B1—Cyclosporine—systemic lupus erythematosus	0.0568	0.109	CbGbCtD
Valsartan—SLCO1B3—Methotrexate—systemic lupus erythematosus	0.0516	0.099	CbGbCtD
Valsartan—ALB—Mycophenolate mofetil—systemic lupus erythematosus	0.041	0.0787	CbGbCtD
Valsartan—CYP2C9—Leflunomide—systemic lupus erythematosus	0.0358	0.0687	CbGbCtD
Valsartan—ALB—Prednisone—systemic lupus erythematosus	0.0328	0.0629	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—systemic lupus erythematosus	0.03	0.0576	CbGbCtD
Valsartan—CYP2C9—Dapsone—systemic lupus erythematosus	0.0255	0.0489	CbGbCtD
Valsartan—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.0168	0.0322	CbGbCtD
Valsartan—ALB—Methotrexate—systemic lupus erythematosus	0.0164	0.0316	CbGbCtD
Valsartan—CYP2C9—cardial valve—systemic lupus erythematosus	0.0129	0.321	CbGeAlD
Valsartan—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.011	0.0212	CbGbCtD
Valsartan—AGTR1—endothelium—systemic lupus erythematosus	0.00339	0.0845	CbGeAlD
Valsartan—AGTR1—blood plasma—systemic lupus erythematosus	0.00301	0.075	CbGeAlD
Valsartan—SLCO1B1—blood plasma—systemic lupus erythematosus	0.00287	0.0715	CbGeAlD
Valsartan—CYP2C9—urine—systemic lupus erythematosus	0.00278	0.0692	CbGeAlD
Valsartan—AGTR1—connective tissue—systemic lupus erythematosus	0.0016	0.0399	CbGeAlD
Valsartan—SLCO1B3—lung—systemic lupus erythematosus	0.00159	0.0397	CbGeAlD
Valsartan—AGTR1—nephron tubule—systemic lupus erythematosus	0.00155	0.0387	CbGeAlD
Valsartan—CYP2C9—blood plasma—systemic lupus erythematosus	0.00145	0.0361	CbGeAlD
Valsartan—AGTR1—kidney—systemic lupus erythematosus	0.00136	0.034	CbGeAlD
Valsartan—AGTR1—cortex of kidney—systemic lupus erythematosus	0.00133	0.0331	CbGeAlD
Valsartan—SLCO1B1—kidney—systemic lupus erythematosus	0.0013	0.0324	CbGeAlD
Valsartan—AGTR1—Allograft Rejection—IL21—systemic lupus erythematosus	0.00117	0.0514	CbGpPWpGaD
Valsartan—AGTR1—lymphoid tissue—systemic lupus erythematosus	0.00117	0.0292	CbGeAlD
Valsartan—AGTR1—tendon—systemic lupus erythematosus	0.0011	0.0275	CbGeAlD
Valsartan—AGTR1—ACE Inhibitor Pathway—ACE—systemic lupus erythematosus	0.000971	0.0426	CbGpPWpGaD
Valsartan—AGTR1—lung—systemic lupus erythematosus	0.000967	0.0241	CbGeAlD
Valsartan—AGTR1—nervous system—systemic lupus erythematosus	0.000895	0.0223	CbGeAlD
Valsartan—AGTR1—central nervous system—systemic lupus erythematosus	0.000862	0.0215	CbGeAlD
Valsartan—SLCO1B3—Recycling of bile acids and salts—RXRA—systemic lupus erythematosus	0.000762	0.0334	CbGpPWpGaD
Valsartan—SLCO1B3—Transport of organic anions—ALB—systemic lupus erythematosus	0.000584	0.0256	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—C4A—systemic lupus erythematosus	0.000573	0.0251	CbGpPWpGaD
Valsartan—SLCO1B1—Recycling of bile acids and salts—RXRA—systemic lupus erythematosus	0.000512	0.0224	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ETS1—systemic lupus erythematosus	0.000498	0.0218	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—NOS3—systemic lupus erythematosus	0.000452	0.0198	CbGpPWpGaD
Valsartan—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—systemic lupus erythematosus	0.000442	0.0194	CbGpPWpGaD
Valsartan—SLCO1B3—Recycling of bile acids and salts—ALB—systemic lupus erythematosus	0.000433	0.019	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—FOXP3—systemic lupus erythematosus	0.000401	0.0176	CbGpPWpGaD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—RXRA—systemic lupus erythematosus	0.000399	0.0175	CbGpPWpGaD
Valsartan—SLCO1B1—Transport of organic anions—ALB—systemic lupus erythematosus	0.000392	0.0172	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC15A4—systemic lupus erythematosus	0.000322	0.0141	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL17A—systemic lupus erythematosus	0.000316	0.0138	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—TGFB1—systemic lupus erythematosus	0.000299	0.0131	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL12B—systemic lupus erythematosus	0.000293	0.0129	CbGpPWpGaD
Valsartan—ALB—Recycling of bile acids and salts—RXRA—systemic lupus erythematosus	0.000293	0.0128	CbGpPWpGaD
Valsartan—SLCO1B1—Recycling of bile acids and salts—ALB—systemic lupus erythematosus	0.000291	0.0127	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CXCL12—systemic lupus erythematosus	0.000283	0.0124	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CD40—systemic lupus erythematosus	0.00028	0.0123	CbGpPWpGaD
Valsartan—Losartan—ACE—systemic lupus erythematosus	0.000279	0.709	CrCbGaD
Valsartan—AGTR1—Allograft Rejection—CTLA4—systemic lupus erythematosus	0.000276	0.0121	CbGpPWpGaD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—RXRA—systemic lupus erythematosus	0.000268	0.0117	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-DQA1—systemic lupus erythematosus	0.000243	0.0106	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—F2—systemic lupus erythematosus	0.00024	0.0105	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-DQB1—systemic lupus erythematosus	0.000227	0.00995	CbGpPWpGaD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—systemic lupus erythematosus	0.000226	0.00991	CbGpPWpGaD
Valsartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—systemic lupus erythematosus	0.000217	0.00949	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC15A4—systemic lupus erythematosus	0.000216	0.00948	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CD40LG—systemic lupus erythematosus	0.000215	0.0094	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL10—systemic lupus erythematosus	0.000215	0.0094	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL4—systemic lupus erythematosus	0.000209	0.00914	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CCR5—systemic lupus erythematosus	0.000204	0.00896	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—FASLG—systemic lupus erythematosus	0.000199	0.00874	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—FAS—systemic lupus erythematosus	0.000192	0.00843	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL2RA—systemic lupus erythematosus	0.000191	0.00838	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic lupus erythematosus	0.000191	0.00835	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—C3—systemic lupus erythematosus	0.00019	0.00831	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-DRB1—systemic lupus erythematosus	0.000173	0.00757	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	0.000164	0.00717	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—P2RY12—systemic lupus erythematosus	0.000163	0.00715	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CD80—systemic lupus erythematosus	0.00016	0.00699	CbGpPWpGaD
Valsartan—ALB—Bile acid and bile salt metabolism—RXRA—systemic lupus erythematosus	0.000153	0.0067	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—systemic lupus erythematosus	0.000152	0.00668	CbGpPWpGaD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—systemic lupus erythematosus	0.000152	0.00666	CbGpPWpGaD
Valsartan—Shock—Triamcinolone—systemic lupus erythematosus	0.000149	0.00118	CcSEcCtD
Valsartan—Insomnia—Prednisolone—systemic lupus erythematosus	0.000149	0.00118	CcSEcCtD
Valsartan—Alopecia—Prednisone—systemic lupus erythematosus	0.000149	0.00118	CcSEcCtD
Valsartan—Shock—Methylprednisolone—systemic lupus erythematosus	0.000149	0.00117	CcSEcCtD
Valsartan—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	0.000149	0.00117	CcSEcCtD
Valsartan—Gastrointestinal pain—Cyclosporine—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Loss of consciousness—Betamethasone—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Loss of consciousness—Dexamethasone—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Paraesthesia—Prednisolone—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Rash—Leflunomide—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Dermatitis—Leflunomide—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Mental disorder—Prednisone—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Nausea—Azathioprine—systemic lupus erythematosus	0.000148	0.00117	CcSEcCtD
Valsartan—Headache—Leflunomide—systemic lupus erythematosus	0.000147	0.00116	CcSEcCtD
Valsartan—Skin disorder—Methylprednisolone—systemic lupus erythematosus	0.000147	0.00116	CcSEcCtD
Valsartan—Malnutrition—Prednisone—systemic lupus erythematosus	0.000147	0.00116	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	0.000147	0.00116	CcSEcCtD
Valsartan—Insomnia—Hydrocortisone—systemic lupus erythematosus	0.000146	0.00115	CcSEcCtD
Valsartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—systemic lupus erythematosus	0.000146	0.00638	CbGpPWpGaD
Valsartan—Paraesthesia—Hydrocortisone—systemic lupus erythematosus	0.000145	0.00114	CcSEcCtD
Valsartan—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000145	0.00114	CcSEcCtD
Valsartan—Urticaria—Cyclosporine—systemic lupus erythematosus	0.000144	0.00114	CcSEcCtD
Valsartan—ALB—Platelet degranulation—CLU—systemic lupus erythematosus	0.000144	0.00631	CbGpPWpGaD
Valsartan—Myalgia—Betamethasone—systemic lupus erythematosus	0.000144	0.00113	CcSEcCtD
Valsartan—Myalgia—Dexamethasone—systemic lupus erythematosus	0.000144	0.00113	CcSEcCtD
Valsartan—Abdominal pain—Cyclosporine—systemic lupus erythematosus	0.000143	0.00113	CcSEcCtD
Valsartan—Anxiety—Betamethasone—systemic lupus erythematosus	0.000143	0.00113	CcSEcCtD
Valsartan—Anxiety—Dexamethasone—systemic lupus erythematosus	0.000143	0.00113	CcSEcCtD
Valsartan—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	0.000142	0.00112	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—systemic lupus erythematosus	0.000142	0.00112	CcSEcCtD
Valsartan—Hypotension—Methylprednisolone—systemic lupus erythematosus	0.000142	0.00112	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—systemic lupus erythematosus	0.000141	0.00111	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—systemic lupus erythematosus	0.000141	0.00111	CcSEcCtD
Valsartan—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	0.000141	0.00111	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL12—systemic lupus erythematosus	0.00014	0.00615	CbGpPWpGaD
Valsartan—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	0.00014	0.0011	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—systemic lupus erythematosus	0.00014	0.0011	CcSEcCtD
Valsartan—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.00014	0.0011	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—P2RY12—systemic lupus erythematosus	0.00014	0.00613	CbGpPWpGaD
Valsartan—Nausea—Leflunomide—systemic lupus erythematosus	0.00014	0.0011	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	0.000139	0.0011	CcSEcCtD
Valsartan—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	0.000139	0.0011	CcSEcCtD
Valsartan—Fatigue—Hydrocortisone—systemic lupus erythematosus	0.000139	0.0011	CcSEcCtD
Valsartan—Vision blurred—Prednisone—systemic lupus erythematosus	0.000139	0.00109	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—Oedema—Dexamethasone—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—Oedema—Betamethasone—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	0.000138	0.00109	CcSEcCtD
Valsartan—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000138	0.00603	CbGpPWpGaD
Valsartan—Insomnia—Triamcinolone—systemic lupus erythematosus	0.000137	0.00108	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—CLU—systemic lupus erythematosus	0.000137	0.00601	CbGpPWpGaD
Valsartan—Insomnia—Methylprednisolone—systemic lupus erythematosus	0.000137	0.00108	CcSEcCtD
Valsartan—Infection—Betamethasone—systemic lupus erythematosus	0.000137	0.00108	CcSEcCtD
Valsartan—Infection—Dexamethasone—systemic lupus erythematosus	0.000137	0.00108	CcSEcCtD
Valsartan—Paraesthesia—Triamcinolone—systemic lupus erythematosus	0.000136	0.00107	CcSEcCtD
Valsartan—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	0.000136	0.00107	CcSEcCtD
Valsartan—Shock—Dexamethasone—systemic lupus erythematosus	0.000136	0.00107	CcSEcCtD
Valsartan—Shock—Betamethasone—systemic lupus erythematosus	0.000136	0.00107	CcSEcCtD
Valsartan—Dyspnoea—Triamcinolone—systemic lupus erythematosus	0.000135	0.00107	CcSEcCtD
Valsartan—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	0.000135	0.00106	CcSEcCtD
Valsartan—Nervous system disorder—Betamethasone—systemic lupus erythematosus	0.000135	0.00106	CcSEcCtD
Valsartan—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	0.000135	0.00106	CcSEcCtD
Valsartan—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	0.000135	0.00106	CcSEcCtD
Valsartan—Angioedema—Prednisone—systemic lupus erythematosus	0.000134	0.00106	CcSEcCtD
Valsartan—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	0.000134	0.00105	CcSEcCtD
Valsartan—Dyspepsia—Triamcinolone—systemic lupus erythematosus	0.000134	0.00105	CcSEcCtD
Valsartan—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	0.000133	0.00105	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—RASGRP1—systemic lupus erythematosus	0.000133	0.00581	CbGpPWpGaD
Valsartan—Vertigo—Prednisone—systemic lupus erythematosus	0.000132	0.00104	CcSEcCtD
Valsartan—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	0.000132	0.00104	CcSEcCtD
Valsartan—Syncope—Prednisone—systemic lupus erythematosus	0.000132	0.00104	CcSEcCtD
Valsartan—Anorexia—Dexamethasone—systemic lupus erythematosus	0.000131	0.00103	CcSEcCtD
Valsartan—Anorexia—Betamethasone—systemic lupus erythematosus	0.000131	0.00103	CcSEcCtD
Valsartan—Urticaria—Prednisolone—systemic lupus erythematosus	0.000131	0.00103	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—systemic lupus erythematosus	0.000131	0.00103	CcSEcCtD
Valsartan—Fatigue—Triamcinolone—systemic lupus erythematosus	0.000131	0.00103	CcSEcCtD
Valsartan—Fatigue—Methylprednisolone—systemic lupus erythematosus	0.000131	0.00103	CcSEcCtD
Valsartan—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	0.00013	0.00103	CcSEcCtD
Valsartan—Asthenia—Cyclosporine—systemic lupus erythematosus	0.00013	0.00103	CcSEcCtD
Valsartan—Loss of consciousness—Prednisone—systemic lupus erythematosus	0.000129	0.00102	CcSEcCtD
Valsartan—Hypotension—Dexamethasone—systemic lupus erythematosus	0.000129	0.00101	CcSEcCtD
Valsartan—Hypotension—Betamethasone—systemic lupus erythematosus	0.000129	0.00101	CcSEcCtD
Valsartan—Pruritus—Cyclosporine—systemic lupus erythematosus	0.000128	0.00101	CcSEcCtD
Valsartan—Urticaria—Hydrocortisone—systemic lupus erythematosus	0.000128	0.00101	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—systemic lupus erythematosus	0.000128	0.00101	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—systemic lupus erythematosus	0.000127	0.001	CcSEcCtD
Valsartan—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	0.000127	0.001	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	0.000127	0.001	CcSEcCtD
Valsartan—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	0.000127	0.001	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IFNG—systemic lupus erythematosus	0.000126	0.00553	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	0.000126	0.000989	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	0.000126	0.000989	CcSEcCtD
Valsartan—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	0.000125	0.000987	CcSEcCtD
Valsartan—Myalgia—Prednisone—systemic lupus erythematosus	0.000125	0.000986	CcSEcCtD
Valsartan—Arthralgia—Prednisone—systemic lupus erythematosus	0.000125	0.000986	CcSEcCtD
Valsartan—Anxiety—Prednisone—systemic lupus erythematosus	0.000125	0.000983	CcSEcCtD
Valsartan—Alopecia—Methotrexate—systemic lupus erythematosus	0.000125	0.000983	CcSEcCtD
Valsartan—Insomnia—Dexamethasone—systemic lupus erythematosus	0.000125	0.000982	CcSEcCtD
Valsartan—Insomnia—Betamethasone—systemic lupus erythematosus	0.000125	0.000982	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	0.000124	0.000979	CcSEcCtD
Valsartan—Diarrhoea—Cyclosporine—systemic lupus erythematosus	0.000124	0.000978	CcSEcCtD
Valsartan—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	0.000124	0.000976	CcSEcCtD
Valsartan—Paraesthesia—Betamethasone—systemic lupus erythematosus	0.000124	0.000975	CcSEcCtD
Valsartan—Paraesthesia—Dexamethasone—systemic lupus erythematosus	0.000124	0.000975	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—systemic lupus erythematosus	0.000124	0.000974	CcSEcCtD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC15A4—systemic lupus erythematosus	0.000124	0.00541	CbGpPWpGaD
Valsartan—Malnutrition—Methotrexate—systemic lupus erythematosus	0.000123	0.000968	CcSEcCtD
Valsartan—Hypersensitivity—Prednisolone—systemic lupus erythematosus	0.000122	0.000959	CcSEcCtD
Valsartan—Dyspepsia—Dexamethasone—systemic lupus erythematosus	0.000121	0.000956	CcSEcCtD
Valsartan—Dyspepsia—Betamethasone—systemic lupus erythematosus	0.000121	0.000956	CcSEcCtD
Valsartan—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	0.000121	0.000954	CcSEcCtD
Valsartan—Urticaria—Triamcinolone—systemic lupus erythematosus	0.000121	0.000951	CcSEcCtD
Valsartan—Urticaria—Methylprednisolone—systemic lupus erythematosus	0.00012	0.000948	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—systemic lupus erythematosus	0.00012	0.000948	CcSEcCtD
Valsartan—Dizziness—Cyclosporine—systemic lupus erythematosus	0.00012	0.000946	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—systemic lupus erythematosus	0.00012	0.000945	CcSEcCtD
Valsartan—Oedema—Prednisone—systemic lupus erythematosus	0.00012	0.000945	CcSEcCtD
Valsartan—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	0.00012	0.000944	CcSEcCtD
Valsartan—Decreased appetite—Dexamethasone—systemic lupus erythematosus	0.00012	0.000944	CcSEcCtD
Valsartan—Decreased appetite—Betamethasone—systemic lupus erythematosus	0.00012	0.000944	CcSEcCtD
Valsartan—Infection—Prednisone—systemic lupus erythematosus	0.000119	0.000939	CcSEcCtD
Valsartan—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	0.000119	0.000937	CcSEcCtD
Valsartan—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	0.000119	0.000937	CcSEcCtD
Valsartan—Back pain—Methotrexate—systemic lupus erythematosus	0.000119	0.000937	CcSEcCtD
Valsartan—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	0.000119	0.000936	CcSEcCtD
Valsartan—Fatigue—Dexamethasone—systemic lupus erythematosus	0.000119	0.000936	CcSEcCtD
Valsartan—Fatigue—Betamethasone—systemic lupus erythematosus	0.000119	0.000936	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	0.000119	0.0052	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—systemic lupus erythematosus	0.000119	0.00519	CbGpPWpGaD
Valsartan—Shock—Prednisone—systemic lupus erythematosus	0.000118	0.00093	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—systemic lupus erythematosus	0.000118	0.00516	CbGpPWpGaD
Valsartan—Nervous system disorder—Prednisone—systemic lupus erythematosus	0.000118	0.000927	CcSEcCtD
Valsartan—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	0.000117	0.000922	CcSEcCtD
Valsartan—Skin disorder—Prednisone—systemic lupus erythematosus	0.000117	0.000918	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—systemic lupus erythematosus	0.000116	0.000912	CcSEcCtD
Valsartan—Asthenia—Hydrocortisone—systemic lupus erythematosus	0.000116	0.000912	CcSEcCtD
Valsartan—Vomiting—Cyclosporine—systemic lupus erythematosus	0.000115	0.000909	CcSEcCtD
Valsartan—Rash—Cyclosporine—systemic lupus erythematosus	0.000114	0.000902	CcSEcCtD
Valsartan—Anorexia—Prednisone—systemic lupus erythematosus	0.000114	0.000901	CcSEcCtD
Valsartan—Losartan—ALB—systemic lupus erythematosus	0.000114	0.291	CrCbGaD
Valsartan—Dermatitis—Cyclosporine—systemic lupus erythematosus	0.000114	0.000901	CcSEcCtD
Valsartan—Pruritus—Hydrocortisone—systemic lupus erythematosus	0.000114	0.000899	CcSEcCtD
Valsartan—Headache—Cyclosporine—systemic lupus erythematosus	0.000114	0.000896	CcSEcCtD
Valsartan—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	0.000113	0.000888	CcSEcCtD
Valsartan—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	0.000113	0.000888	CcSEcCtD
Valsartan—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	0.000113	0.000887	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL2—systemic lupus erythematosus	0.000112	0.00491	CbGpPWpGaD
Valsartan—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	0.000112	0.000882	CcSEcCtD
Valsartan—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	0.000112	0.00088	CcSEcCtD
Valsartan—Rash—Mycophenolate mofetil—systemic lupus erythematosus	0.000112	0.000879	CcSEcCtD
Valsartan—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	0.000112	0.000879	CcSEcCtD
Valsartan—Headache—Mycophenolate mofetil—systemic lupus erythematosus	0.000111	0.000874	CcSEcCtD
Valsartan—Vertigo—Methotrexate—systemic lupus erythematosus	0.00011	0.00087	CcSEcCtD
Valsartan—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	0.00011	0.000869	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	0.00011	0.00482	CbGpPWpGaD
Valsartan—Urticaria—Betamethasone—systemic lupus erythematosus	0.000109	0.000862	CcSEcCtD
Valsartan—Urticaria—Dexamethasone—systemic lupus erythematosus	0.000109	0.000862	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	0.000109	0.000861	CcSEcCtD
Valsartan—Dizziness—Prednisolone—systemic lupus erythematosus	0.000109	0.00086	CcSEcCtD
Valsartan—Asthenia—Triamcinolone—systemic lupus erythematosus	0.000109	0.000858	CcSEcCtD
Valsartan—Abdominal pain—Betamethasone—systemic lupus erythematosus	0.000109	0.000858	CcSEcCtD
Valsartan—Abdominal pain—Dexamethasone—systemic lupus erythematosus	0.000109	0.000858	CcSEcCtD
Valsartan—Asthenia—Methylprednisolone—systemic lupus erythematosus	0.000109	0.000857	CcSEcCtD
Valsartan—Insomnia—Prednisone—systemic lupus erythematosus	0.000109	0.000855	CcSEcCtD
Valsartan—Nausea—Cyclosporine—systemic lupus erythematosus	0.000108	0.000849	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—systemic lupus erythematosus	0.000108	0.000849	CcSEcCtD
Valsartan—Pruritus—Triamcinolone—systemic lupus erythematosus	0.000107	0.000847	CcSEcCtD
Valsartan—Cough—Methotrexate—systemic lupus erythematosus	0.000107	0.000845	CcSEcCtD
Valsartan—Pruritus—Methylprednisolone—systemic lupus erythematosus	0.000107	0.000845	CcSEcCtD
Valsartan—Dizziness—Hydrocortisone—systemic lupus erythematosus	0.000107	0.00084	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—P2RY12—systemic lupus erythematosus	0.000107	0.00467	CbGpPWpGaD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—systemic lupus erythematosus	0.000106	0.00465	CbGpPWpGaD
Valsartan—Dyspepsia—Prednisone—systemic lupus erythematosus	0.000106	0.000832	CcSEcCtD
Valsartan—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	0.000105	0.000828	CcSEcCtD
Valsartan—Chest pain—Methotrexate—systemic lupus erythematosus	0.000105	0.000824	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—systemic lupus erythematosus	0.000105	0.000824	CcSEcCtD
Valsartan—Myalgia—Methotrexate—systemic lupus erythematosus	0.000105	0.000824	CcSEcCtD
Valsartan—Decreased appetite—Prednisone—systemic lupus erythematosus	0.000104	0.000822	CcSEcCtD
Valsartan—Rash—Prednisolone—systemic lupus erythematosus	0.000104	0.00082	CcSEcCtD
Valsartan—Dermatitis—Prednisolone—systemic lupus erythematosus	0.000104	0.00082	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	0.000104	0.000819	CcSEcCtD
Valsartan—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	0.000104	0.000817	CcSEcCtD
Valsartan—Fatigue—Prednisone—systemic lupus erythematosus	0.000103	0.000815	CcSEcCtD
Valsartan—Headache—Prednisolone—systemic lupus erythematosus	0.000103	0.000815	CcSEcCtD
Valsartan—Constipation—Prednisone—systemic lupus erythematosus	0.000103	0.000809	CcSEcCtD
Valsartan—Vomiting—Hydrocortisone—systemic lupus erythematosus	0.000103	0.000808	CcSEcCtD
Valsartan—Rash—Hydrocortisone—systemic lupus erythematosus	0.000102	0.000801	CcSEcCtD
Valsartan—Dermatitis—Hydrocortisone—systemic lupus erythematosus	0.000102	0.0008	CcSEcCtD
Valsartan—Headache—Hydrocortisone—systemic lupus erythematosus	0.000101	0.000796	CcSEcCtD
Valsartan—Dizziness—Triamcinolone—systemic lupus erythematosus	0.0001	0.000791	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	0.0001	0.00079	CcSEcCtD
Valsartan—Dizziness—Methylprednisolone—systemic lupus erythematosus	0.0001	0.000789	CcSEcCtD
Valsartan—Infection—Methotrexate—systemic lupus erythematosus	9.96e-05	0.000785	CcSEcCtD
Valsartan—Asthenia—Betamethasone—systemic lupus erythematosus	9.89e-05	0.000779	CcSEcCtD
Valsartan—Asthenia—Dexamethasone—systemic lupus erythematosus	9.89e-05	0.000779	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—systemic lupus erythematosus	9.83e-05	0.000775	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	9.82e-05	0.000774	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	9.81e-05	0.000773	CcSEcCtD
Valsartan—Nausea—Prednisolone—systemic lupus erythematosus	9.81e-05	0.000773	CcSEcCtD
Valsartan—Pruritus—Dexamethasone—systemic lupus erythematosus	9.75e-05	0.000768	CcSEcCtD
Valsartan—Pruritus—Betamethasone—systemic lupus erythematosus	9.75e-05	0.000768	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—systemic lupus erythematosus	9.74e-05	0.000768	CcSEcCtD
Valsartan—Vomiting—Triamcinolone—systemic lupus erythematosus	9.65e-05	0.000761	CcSEcCtD
Valsartan—Vomiting—Methylprednisolone—systemic lupus erythematosus	9.63e-05	0.000759	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR5—systemic lupus erythematosus	9.62e-05	0.00421	CbGpPWpGaD
Valsartan—Nausea—Hydrocortisone—systemic lupus erythematosus	9.58e-05	0.000755	CcSEcCtD
Valsartan—Rash—Triamcinolone—systemic lupus erythematosus	9.57e-05	0.000754	CcSEcCtD
Valsartan—Dermatitis—Triamcinolone—systemic lupus erythematosus	9.57e-05	0.000754	CcSEcCtD
Valsartan—Anorexia—Methotrexate—systemic lupus erythematosus	9.56e-05	0.000753	CcSEcCtD
Valsartan—Rash—Methylprednisolone—systemic lupus erythematosus	9.55e-05	0.000753	CcSEcCtD
Valsartan—Dermatitis—Methylprednisolone—systemic lupus erythematosus	9.54e-05	0.000752	CcSEcCtD
Valsartan—Urticaria—Prednisone—systemic lupus erythematosus	9.53e-05	0.000751	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—VEGFA—systemic lupus erythematosus	9.53e-05	0.00417	CbGpPWpGaD
Valsartan—Headache—Triamcinolone—systemic lupus erythematosus	9.51e-05	0.00075	CcSEcCtD
Valsartan—Headache—Methylprednisolone—systemic lupus erythematosus	9.49e-05	0.000748	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—systemic lupus erythematosus	9.49e-05	0.000747	CcSEcCtD
Valsartan—Diarrhoea—Betamethasone—systemic lupus erythematosus	9.43e-05	0.000743	CcSEcCtD
Valsartan—Diarrhoea—Dexamethasone—systemic lupus erythematosus	9.43e-05	0.000743	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—systemic lupus erythematosus	9.41e-05	0.00412	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—C3—systemic lupus erythematosus	9.4e-05	0.00412	CbGpPWpGaD
Valsartan—Hypotension—Methotrexate—systemic lupus erythematosus	9.37e-05	0.000738	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—systemic lupus erythematosus	9.19e-05	0.00403	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	9.14e-05	0.00072	CcSEcCtD
Valsartan—Dizziness—Dexamethasone—systemic lupus erythematosus	9.11e-05	0.000718	CcSEcCtD
Valsartan—Dizziness—Betamethasone—systemic lupus erythematosus	9.11e-05	0.000718	CcSEcCtD
Valsartan—Insomnia—Methotrexate—systemic lupus erythematosus	9.07e-05	0.000715	CcSEcCtD
Valsartan—Nausea—Triamcinolone—systemic lupus erythematosus	9.02e-05	0.000711	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—systemic lupus erythematosus	9e-05	0.00071	CcSEcCtD
Valsartan—Nausea—Methylprednisolone—systemic lupus erythematosus	9e-05	0.000709	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—systemic lupus erythematosus	8.94e-05	0.000704	CcSEcCtD
Valsartan—Somnolence—Methotrexate—systemic lupus erythematosus	8.91e-05	0.000702	CcSEcCtD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—F2—systemic lupus erythematosus	8.91e-05	0.0039	CbGpPWpGaD
Valsartan—Hypersensitivity—Prednisone—systemic lupus erythematosus	8.84e-05	0.000697	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—systemic lupus erythematosus	8.83e-05	0.000696	CcSEcCtD
Valsartan—Vomiting—Betamethasone—systemic lupus erythematosus	8.76e-05	0.00069	CcSEcCtD
Valsartan—Vomiting—Dexamethasone—systemic lupus erythematosus	8.76e-05	0.00069	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TGFB1—systemic lupus erythematosus	8.75e-05	0.00383	CbGpPWpGaD
Valsartan—Decreased appetite—Methotrexate—systemic lupus erythematosus	8.72e-05	0.000687	CcSEcCtD
Valsartan—Rash—Betamethasone—systemic lupus erythematosus	8.69e-05	0.000685	CcSEcCtD
Valsartan—Rash—Dexamethasone—systemic lupus erythematosus	8.69e-05	0.000685	CcSEcCtD
Valsartan—Dermatitis—Dexamethasone—systemic lupus erythematosus	8.68e-05	0.000684	CcSEcCtD
Valsartan—Dermatitis—Betamethasone—systemic lupus erythematosus	8.68e-05	0.000684	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	8.66e-05	0.000682	CcSEcCtD
Valsartan—Fatigue—Methotrexate—systemic lupus erythematosus	8.65e-05	0.000681	CcSEcCtD
Valsartan—Headache—Betamethasone—systemic lupus erythematosus	8.63e-05	0.00068	CcSEcCtD
Valsartan—Headache—Dexamethasone—systemic lupus erythematosus	8.63e-05	0.00068	CcSEcCtD
Valsartan—Asthenia—Prednisone—systemic lupus erythematosus	8.61e-05	0.000678	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CRP—systemic lupus erythematosus	8.58e-05	0.00376	CbGpPWpGaD
Valsartan—Pruritus—Prednisone—systemic lupus erythematosus	8.49e-05	0.000669	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—F2—systemic lupus erythematosus	8.36e-05	0.00366	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	8.32e-05	0.00365	CbGpPWpGaD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	8.28e-05	0.00363	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—F2—systemic lupus erythematosus	8.25e-05	0.00361	CbGpPWpGaD
Valsartan—Diarrhoea—Prednisone—systemic lupus erythematosus	8.21e-05	0.000647	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	8.2e-05	0.000646	CcSEcCtD
Valsartan—Nausea—Dexamethasone—systemic lupus erythematosus	8.18e-05	0.000645	CcSEcCtD
Valsartan—Nausea—Betamethasone—systemic lupus erythematosus	8.18e-05	0.000645	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—systemic lupus erythematosus	8.17e-05	0.00358	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL4—systemic lupus erythematosus	8.07e-05	0.00354	CbGpPWpGaD
Valsartan—Urticaria—Methotrexate—systemic lupus erythematosus	7.97e-05	0.000628	CcSEcCtD
Valsartan—Dizziness—Prednisone—systemic lupus erythematosus	7.93e-05	0.000625	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—systemic lupus erythematosus	7.93e-05	0.000625	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—F2—systemic lupus erythematosus	7.92e-05	0.00347	CbGpPWpGaD
Valsartan—Vomiting—Prednisone—systemic lupus erythematosus	7.63e-05	0.000601	CcSEcCtD
Valsartan—Rash—Prednisone—systemic lupus erythematosus	7.57e-05	0.000596	CcSEcCtD
Valsartan—Dermatitis—Prednisone—systemic lupus erythematosus	7.56e-05	0.000596	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—systemic lupus erythematosus	7.53e-05	0.0033	CbGpPWpGaD
Valsartan—Headache—Prednisone—systemic lupus erythematosus	7.52e-05	0.000592	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—systemic lupus erythematosus	7.47e-05	0.00327	CbGpPWpGaD
Valsartan—Hypersensitivity—Methotrexate—systemic lupus erythematosus	7.39e-05	0.000582	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL2—systemic lupus erythematosus	7.35e-05	0.00322	CbGpPWpGaD
Valsartan—Asthenia—Methotrexate—systemic lupus erythematosus	7.19e-05	0.000567	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CXCL12—systemic lupus erythematosus	7.17e-05	0.00314	CbGpPWpGaD
Valsartan—Nausea—Prednisone—systemic lupus erythematosus	7.13e-05	0.000562	CcSEcCtD
Valsartan—Pruritus—Methotrexate—systemic lupus erythematosus	7.09e-05	0.000559	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CCL2—systemic lupus erythematosus	7.05e-05	0.00309	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—CRP—systemic lupus erythematosus	6.98e-05	0.00306	CbGpPWpGaD
Valsartan—Diarrhoea—Methotrexate—systemic lupus erythematosus	6.86e-05	0.000541	CcSEcCtD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	6.75e-05	0.00296	CbGpPWpGaD
Valsartan—Dizziness—Methotrexate—systemic lupus erythematosus	6.63e-05	0.000523	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—systemic lupus erythematosus	6.45e-05	0.00283	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—F2—systemic lupus erythematosus	6.44e-05	0.00282	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—NAT2—systemic lupus erythematosus	6.39e-05	0.0028	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—CLU—systemic lupus erythematosus	6.39e-05	0.0028	CbGpPWpGaD
Valsartan—Vomiting—Methotrexate—systemic lupus erythematosus	6.38e-05	0.000502	CcSEcCtD
Valsartan—Rash—Methotrexate—systemic lupus erythematosus	6.32e-05	0.000498	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—systemic lupus erythematosus	6.32e-05	0.000498	CcSEcCtD
Valsartan—CYP2C9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	6.3e-05	0.00276	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—C3—systemic lupus erythematosus	6.3e-05	0.00276	CbGpPWpGaD
Valsartan—Headache—Methotrexate—systemic lupus erythematosus	6.28e-05	0.000495	CcSEcCtD
Valsartan—ALB—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	6.28e-05	0.00275	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—P2RY12—systemic lupus erythematosus	6.19e-05	0.00271	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—systemic lupus erythematosus	6.05e-05	0.00265	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—P2RY12—systemic lupus erythematosus	6.02e-05	0.00264	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IFNG—systemic lupus erythematosus	6e-05	0.00263	CbGpPWpGaD
Valsartan—Nausea—Methotrexate—systemic lupus erythematosus	5.96e-05	0.000469	CcSEcCtD
Valsartan—ALB—Folate Metabolism—CCL2—systemic lupus erythematosus	5.74e-05	0.00251	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—CSK—systemic lupus erythematosus	5.7e-05	0.0025	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—CRP—systemic lupus erythematosus	5.54e-05	0.00243	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—systemic lupus erythematosus	5.53e-05	0.00242	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—P2RY12—systemic lupus erythematosus	5.47e-05	0.00239	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—LYN—systemic lupus erythematosus	5.18e-05	0.00227	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—F2—systemic lupus erythematosus	5.12e-05	0.00224	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic lupus erythematosus	4.93e-05	0.00216	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCR5—systemic lupus erythematosus	4.91e-05	0.00215	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IFNG—systemic lupus erythematosus	4.88e-05	0.00214	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—C3—systemic lupus erythematosus	4.8e-05	0.0021	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	4.78e-05	0.00209	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—systemic lupus erythematosus	4.65e-05	0.00204	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	4.56e-05	0.002	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	4.38e-05	0.00192	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL2—systemic lupus erythematosus	4.34e-05	0.0019	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—F2—systemic lupus erythematosus	4.21e-05	0.00185	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	4.16e-05	0.00182	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL12—systemic lupus erythematosus	4.05e-05	0.00177	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RASGRP1—systemic lupus erythematosus	3.88e-05	0.0017	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—systemic lupus erythematosus	3.88e-05	0.0017	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	3.88e-05	0.0017	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—RASGRP1—systemic lupus erythematosus	3.78e-05	0.00165	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCL2—systemic lupus erythematosus	3.76e-05	0.00165	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—systemic lupus erythematosus	3.72e-05	0.00163	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGAX—systemic lupus erythematosus	3.7e-05	0.00162	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL12—systemic lupus erythematosus	3.68e-05	0.00161	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F3—systemic lupus erythematosus	3.64e-05	0.0016	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—RXRA—systemic lupus erythematosus	3.58e-05	0.00157	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NAT2—systemic lupus erythematosus	3.48e-05	0.00152	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RASGRP1—systemic lupus erythematosus	3.43e-05	0.0015	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TLR9—systemic lupus erythematosus	3.33e-05	0.00146	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CLU—systemic lupus erythematosus	3.29e-05	0.00144	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—P2RY12—systemic lupus erythematosus	3.23e-05	0.00141	CbGpPWpGaD
Valsartan—ALB—Hemostasis—P2RY12—systemic lupus erythematosus	3.19e-05	0.0014	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—VEGFA—systemic lupus erythematosus	3.16e-05	0.00138	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—systemic lupus erythematosus	3.16e-05	0.00138	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—systemic lupus erythematosus	3.13e-05	0.00137	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—systemic lupus erythematosus	3.13e-05	0.00137	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	3.05e-05	0.00134	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—JAK1—systemic lupus erythematosus	3.01e-05	0.00132	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—systemic lupus erythematosus	3.01e-05	0.00132	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CSK—systemic lupus erythematosus	2.97e-05	0.0013	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—systemic lupus erythematosus	2.96e-05	0.0013	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.94e-05	0.00129	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SELE—systemic lupus erythematosus	2.94e-05	0.00129	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CSK—systemic lupus erythematosus	2.94e-05	0.00129	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—JAK1—systemic lupus erythematosus	2.93e-05	0.00128	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—TGFB1—systemic lupus erythematosus	2.9e-05	0.00127	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2RA—systemic lupus erythematosus	2.81e-05	0.00123	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	2.8e-05	0.00123	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR5—systemic lupus erythematosus	2.78e-05	0.00122	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	2.77e-05	0.00121	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic lupus erythematosus	2.76e-05	0.00121	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGAM—systemic lupus erythematosus	2.76e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2RA—systemic lupus erythematosus	2.74e-05	0.0012	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NCF2—systemic lupus erythematosus	2.72e-05	0.00119	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—C3—systemic lupus erythematosus	2.71e-05	0.00119	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LYN—systemic lupus erythematosus	2.7e-05	0.00118	CbGpPWpGaD
Valsartan—ALB—Hemostasis—LYN—systemic lupus erythematosus	2.67e-05	0.00117	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—JAK1—systemic lupus erythematosus	2.66e-05	0.00117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SH2B3—systemic lupus erythematosus	2.65e-05	0.00116	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SH2B3—systemic lupus erythematosus	2.62e-05	0.00115	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—systemic lupus erythematosus	2.55e-05	0.00112	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR5—systemic lupus erythematosus	2.52e-05	0.0011	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—systemic lupus erythematosus	2.51e-05	0.0011	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	2.49e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2RA—systemic lupus erythematosus	2.48e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—C3—systemic lupus erythematosus	2.46e-05	0.00108	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—F2—systemic lupus erythematosus	2.45e-05	0.00107	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—F2—systemic lupus erythematosus	2.38e-05	0.00104	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	2.36e-05	0.00104	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAT2—systemic lupus erythematosus	2.34e-05	0.00102	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	2.18e-05	0.000953	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL12—systemic lupus erythematosus	2.17e-05	0.000952	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—F2—systemic lupus erythematosus	2.16e-05	0.000947	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUNB—systemic lupus erythematosus	2.13e-05	0.000934	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA1—systemic lupus erythematosus	2.06e-05	0.000901	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RASGRP1—systemic lupus erythematosus	2.03e-05	0.000888	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	2.03e-05	0.000887	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RASGRP1—systemic lupus erythematosus	2e-05	0.000877	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRL—systemic lupus erythematosus	1.97e-05	0.000861	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RXRA—systemic lupus erythematosus	1.95e-05	0.000854	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL2—systemic lupus erythematosus	1.93e-05	0.000844	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.86e-05	0.000814	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.81e-05	0.000792	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TYK2—systemic lupus erythematosus	1.75e-05	0.000767	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.68e-05	0.000736	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.67e-05	0.000732	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—systemic lupus erythematosus	1.65e-05	0.000722	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—systemic lupus erythematosus	1.6e-05	0.000703	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.6e-05	0.0007	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.59e-05	0.000696	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAK1—systemic lupus erythematosus	1.57e-05	0.000688	CbGpPWpGaD
Valsartan—ALB—Hemostasis—JAK1—systemic lupus erythematosus	1.55e-05	0.00068	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR5—systemic lupus erythematosus	1.49e-05	0.000652	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.47e-05	0.000643	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.46e-05	0.00064	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—systemic lupus erythematosus	1.46e-05	0.000638	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—C3—systemic lupus erythematosus	1.46e-05	0.000637	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2RA—systemic lupus erythematosus	1.45e-05	0.000635	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—systemic lupus erythematosus	1.4e-05	0.000614	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.38e-05	0.000603	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAT2—systemic lupus erythematosus	1.34e-05	0.000585	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RXRA—systemic lupus erythematosus	1.31e-05	0.000574	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	1.29e-05	0.000564	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—F2—systemic lupus erythematosus	1.28e-05	0.00056	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F2—systemic lupus erythematosus	1.26e-05	0.000553	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—systemic lupus erythematosus	1.23e-05	0.000539	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD80—systemic lupus erythematosus	1.22e-05	0.000537	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.22e-05	0.000532	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—systemic lupus erythematosus	1.14e-05	0.000499	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—systemic lupus erythematosus	1.11e-05	0.000485	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAT2—systemic lupus erythematosus	1.09e-05	0.000479	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.06e-05	0.000465	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—systemic lupus erythematosus	1.06e-05	0.000464	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TYK2—systemic lupus erythematosus	1.03e-05	0.000453	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—systemic lupus erythematosus	1.02e-05	0.000445	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—systemic lupus erythematosus	1e-05	0.000439	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—systemic lupus erythematosus	9.69e-06	0.000424	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	8.79e-06	0.000385	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	8.69e-06	0.000381	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—systemic lupus erythematosus	8.6e-06	0.000377	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—systemic lupus erythematosus	8.56e-06	0.000375	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—systemic lupus erythematosus	8.5e-06	0.000372	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	8.35e-06	0.000366	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—systemic lupus erythematosus	8.27e-06	0.000362	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—systemic lupus erythematosus	8.14e-06	0.000357	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	8.11e-06	0.000355	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—EP300—systemic lupus erythematosus	8.06e-06	0.000353	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	7.81e-06	0.000342	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EP300—systemic lupus erythematosus	7.72e-06	0.000338	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EP300—systemic lupus erythematosus	7.63e-06	0.000334	CbGpPWpGaD
Valsartan—ALB—Metabolism—RXRA—systemic lupus erythematosus	7.49e-06	0.000328	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—systemic lupus erythematosus	7.44e-06	0.000326	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—systemic lupus erythematosus	7.31e-06	0.00032	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—systemic lupus erythematosus	7.23e-06	0.000316	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—systemic lupus erythematosus	7.12e-06	0.000312	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	6.94e-06	0.000304	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	6.84e-06	0.000299	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—systemic lupus erythematosus	6.71e-06	0.000294	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—systemic lupus erythematosus	6.63e-06	0.00029	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—systemic lupus erythematosus	6.51e-06	0.000285	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	6.13e-06	0.000268	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	5.68e-06	0.000249	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—EP300—systemic lupus erythematosus	5.41e-06	0.000237	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—systemic lupus erythematosus	5.06e-06	0.000222	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—systemic lupus erythematosus	4.73e-06	0.000207	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—systemic lupus erythematosus	4.07e-06	0.000178	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	3.87e-06	0.000169	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—systemic lupus erythematosus	3.72e-06	0.000163	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	3.48e-06	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	3.33e-06	0.000146	CbGpPWpGaD
Valsartan—ALB—Metabolism—EP300—systemic lupus erythematosus	3.09e-06	0.000135	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	3.04e-06	0.000133	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	2.53e-06	0.000111	CbGpPWpGaD
